Literature DB >> 19086606

Minimally invasive staging of N2 disease: endobronchial ultrasound/transesophageal endoscopic ultrasound, mediastinoscopy, and thoracoscopy.

Paul Schipper1, Matt Schoolfield.   

Abstract

In 2005 the American College of Surgeons conducted a survey examining lung cancer practice patterns at 729 hospitals in the United States. In 11,668 surgically treated patients, 92% received a preoperative chest CT. Only 27% of these patients underwent mediastinoscopy, and lymph node material was sampled in less than half of these patients. At the time of surgical resection, additional mediastinal lymph nodes were sampled in only 58% of patients. In the remaining 42% only the lymph node material attached to the surgical specimen (N1 nodes) was sampled. Although this article discusses the finer points of the minimally invasive evaluation of the N2 lymph nodes, any procedure to evaluate these nodes is better than simply ignoring them.

Entities:  

Mesh:

Year:  2008        PMID: 19086606     DOI: 10.1016/j.thorsurg.2008.08.001

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  6 in total

Review 1.  Ultrasound techniques in the evaluation of the mediastinum, part I: endoscopic ultrasound (EUS), endobronchial ultrasound (EBUS) and transcutaneous mediastinal ultrasound (TMUS), introduction into ultrasound techniques.

Authors:  Christoph Frank Dietrich; Jouke Tabe Annema; Paul Clementsen; Xin Wu Cui; Mathias Maximilian Borst; Christian Jenssen
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

2.  Determinants of practice patterns and quality gaps in lung cancer staging and diagnosis.

Authors:  David E Ost; Jiangong Niu; Linda S Elting; Thomas A Buchholz; Sharon H Giordano
Journal:  Chest       Date:  2014-05       Impact factor: 9.410

3.  Endobronchial ultrasound for lung cancer diagnosis and staging: a review of the clinical and cost-effectiveness.

Authors: 
Journal:  CADTH Technol Overv       Date:  2010-06-01

4.  Quality gaps and comparative effectiveness in lung cancer staging and diagnosis.

Authors:  David E Ost; Jiangong Niu; Linda S Elting; Thomas A Buchholz; Sharon H Giordano
Journal:  Chest       Date:  2014-02       Impact factor: 9.410

5.  Quality gaps and comparative effectiveness in lung cancer staging: the impact of test sequencing on outcomes.

Authors:  Francisco A Almeida; Roberto F Casal; Carlos A Jimenez; George A Eapen; Mateen Uzbeck; Mona Sarkiss; David Rice; Rodolfo C Morice; David E Ost
Journal:  Chest       Date:  2013-12       Impact factor: 9.410

6.  Impact of the introduction of EBUS on time to management decision, complications, and invasive modalities used to diagnose and stage lung cancer: a pragmatic pre-post study.

Authors:  Neli S Slavova-Azmanova; Catalina Lizama; Claire E Johnson; Herbert P Ludewick; Leanne Lester; Shanka Karunarathne; Martin Phillips
Journal:  BMC Cancer       Date:  2016-01-28       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.